In previous work on pancreatic cancer using an anti-CEA antibody conjugated to Alexa Fluor 488, median disease-free survival for the FGS group was 11 weeks compared with 5 weeks for the bright-light surgery group.61 The enhanced ability to visualize the gastric tumors at the time of surgery should result in improved resections and thus survival, although studies are needed to test this hypothesis. The gene discussed is CEACAM5; the disease is pancreatic neoplasm.